Journal List > J Korean Soc Spine Surg > v.14(2) > 1035797

Lee: Spine Fusion Surgery for the Patient Refusing Allotransfusion

Abstract

Purpose:

To report the results of spine surgery for patients refusing allotransfusion.

Materials and Methods

The operations were performed for 24 patients who were scheduled to undergo posterolateral fusion with internal fixation between January 2004 and March 2006. There were 7 male and 17 female patients, and the average age of the patients was 54 (range: 12~71) years. All fo these patients were indicated for posterolateral fusion with internal fixation requiring intraoperative and postoperative blood transfusion. In the whole study group, all of the patients refused to receive conventional transfusion therapy because of religious convictions. To categorize the patients by disease, there were 17 cases of spinal stenosis, two cases of spondylolytic spondylolisthesis, four cases of spinal stenosis with degenerative spondylolisthesis, and one case of neurofibromatosis scoliosis. In order to increase hemoglobin level, recombinant human erythropoietin was administered before the operation, and controlled hypotensive anesthesia, acute normovolemic hemodilution, a cell saving system, and reducing operating time methods were intraoperatively used to spare blood in spine surgery. Postoperatively, recuperative techniques were used to decrease blood loss and maximize blood production.

Results

In the entire study group, there were no side effects or associated symptoms following bloodless surgery. In the followup period, there were no side effects or a lack of blood.

Conclusion

Our results suggest that bloodless spinal surgery is an important method that can be used for decreasing the side effects of blood transfusion, and can be considered one of the good modalities with which to satisfy medical demands in spinal surgery.

REFERENCES

1). Clark JM. Surgery in Jehovwah's witnesses. Br J Hosp Med. 1982; 27:497–500.
2). CDC Update. Acquired immunodeficiency syndrome-Unite state 1989. MMWR. 1990; 39:81–84.
3). Curran JW, Lawrence DN, Jaffe H, et al. .:. Acquired immunodeficiency syndrome (AIDS) associated with transfusion. NEJM. 1984; 310:69–75.
4). Goulet JA, Bray TJ, Timmerman LA, Benson DR, Bargar AWL. Intraoperative autologous transfusion in orthopardic patients. J Bone and Joint Surgery Am. 1989; 71(1):3–8.
5). David C, Mann. Decreasing homologous blood transfusion in spinal surgery by use of the cell caver and predict-ed blood. Spine. 1989; 14:1296–1302.
6). Cavallieri S, Riou B, Roche S, et al. .:. Intraoperative autologous transfusion in emergency surgery for spine trauma. J Trauma. 1994; 36:639–643.
crossref
7). Bovill DF, Moulton CW, Jackson WST, Jensen JK. The efficacy of intraoperative autologous transfusion in major orthopedic surgery: A Regression analysis. Orthopedics. 1986; 9:1403–1407.
crossref
8). American Association of Blood Bank. Guidelines for blood salvage and reinfusion in surgery and trauma. 1988-1989 and 1989-1990, AABB, autologous transfusion committee.
9). Simpson MB, Georgopoulos G, Eilert RE. Intraoperative blood salvage in children and young adults undergoing spinal surgery with predeposited autologous blood: Efficacy and cost effectiveness. J Prosthet Orthot. 1993; 13:777–780.
crossref
10). Flynn JC, Metzgr CR, Csencsitz TA. Intraoperative autotransfusion (IAT) in spinal surgery. Spine. 1982; 7:432.
crossref
11). Messer K. Hemodilution. Surg Clin North Am. 1975; 55:659–678.
12). Blundell J. Experiments on the transfusion of blood by syringe. Med Chir Tr. 1818; 9:56–92.
13). Klebanoff G. Early clinical experience with a disposable unit for intraoperative salvage and reinfusion of blood loss (intraoperative autotransfusion). Am J Surg. 1970; 120:718–722.
14). Boudreaux JP, Bornside GH, Cohn I Ir. Emergency autotransfusion; partial cleansing of bacteria-laden blood by cell washing. J Trauma. 1983; 23:31–35.
15). Healy WL, Pfelfer BA, Kurtz SR, et al. .:. Evaluation of autologous shed blood for autotransfusion after orthopaedic surgery. Clin Orthop. 1994; 299:53–58.
crossref
16). Roye DP Jr. Recombinant human erythropoietin and blood management in pediatric spine surgery. Orthopedics. 1999; 22:158–160.
crossref
17). Coyle D, Lee KM, Fergusson DA, et al. .:. Economic analysis of erythropoietin use in orthopaedic surgery. Transfus Med. 1999; 9:21–30.
crossref
18). Lee JH, Lee SH, Oh JH. Minimal effective dosage of recombinant human erthropoietin in spinal surgery. Clin Orthop. 2003; 412:71–76.
19). Mercuriali F, Zanella A, Barsosi G, et al. .:. Use of erthropoietin to increase the volume of autologous blood donated by orthopedic patients. transfusion. 1993; 33:55–60.

Figures and Tables%

Fig. 1.
Postoperative anteroposterior and lateral plain radiographs show posterior decompression and instrumented posterolateral fusion for spinal stenosis.
jkss-14-87f1.tif
Fig. 2.
Postoperative anteroposterior and lateral plain radiographs show scoliosis correction in neurofibromatosis patient.
jkss-14-87f2.tif
Fig. 3.
The average of hemoglobin (g/dl).
jkss-14-87f3.tif
Table 1.
Geographic data about Patient's age, sex, diagnosis and operation name
No Age/Sex Diagnosis Operation name
01 12/F Neurofibromatosis scoliosis Posterior correction with posterior fusion
02 34/M Spondylolytic spondylolisthesis L4 on L5 Posterior decompression and instrumented posterolateral fusion and posterior lumbar interbody fusion L4-5
03 71/M Spinal stenosis L4-5,L5-S1 with degenerative spondylolisthesis L5 on S1 Posterior decompression and instrumented posterolateral fusion L4-5-S1
04 60/F Spinal stenosis L3-4,4-5 Posterior decompression and instrumented posterolateral fusion L3-4-5
05 51/M Spinal stenosis L2-3,3-4,4-5 Posterior decompression and instrumented posterolateral fusion L2-3-4-5
06 48/F Spinal stenosis L3-4,4-5 Posterior decompression and instrumented posterolateral fusion L3-4-5
07 60/F Spinal stenosis L3-4,4-5,L5-S1 Posterior decompression and instrumented posterolateral fusion L3-4-5-S1
08 55/F Spinal stenosis L2-3,3-4 Posterior decompression and instrumented posterolateral fusion 2-3-4
09 53/F Spinal stenosis L3-4,4-5 Posterior decompression and instrumented posterolateral fusion 3-4-5
10 59/F Spinal stenosis L3-4,4-5 with degenerative spondylolisthesis L4 on L5 Posterior decompression and instrumented posterolateral fusion L3-4-5
11 52/F Spinal stenosis L3-4,4-5 Posterior decompression and instrumented posterolateral fusion L3-4-5
12 60/F Spinal stensosis L2-3,3-4,4-5 Posterior decompression and instrumented posterolateral fusion 2-3-4-5
13 50/M Spinal stenosis L2-3,3-4 Posterior decompression and instrumented posterolateral fusion 2-3-4
14 57/F Spinal stenosis L2-3,3-4 Posterior decompression and instrumented posterolateral fusion 2-3-4
15 49/M Spinal stenosis L3-4,4-5 Posterior decompression and instrumented posterolateral fusion 3-4-5
16 43/M Spondylolytic spondylolisthesis L4 on L5 Posterior decompression and instrumented posterolateral fusion and posterior lumbar interbody fusion L4-5
17 57/F Spinal stenosis L4-5,L5-S1 with degenerative spondylolisthesis L5 on S1 Posterior decompression and instrumented posterolateral fusion L4-5,L5-S1
18 67/F Spinal stenosis L3-4,4-5 Posterior decompression and instrumented posterolateral fusion L3-4-5
19 53/F Spinal stenosis L3-4,4-5 Posterior decompression and instrumented posterolateral fusion L3-4-5
20 56/F Spinal stenosis L2-3,3-4,4-5 with degenerative spondylolisthesis L4 on L5 Posterior decompression and instrumented posterolateral fusion L2-3-4-5
21 55/F Spinal stenosis L3-4,4-5 Posterior decompression and instrumented posterolateral fusion L3-4-5
22 65/F Spinal stenosis L2-3,3-4 Posterior decompression and instrumented posterolateral fusion L2-3-4
23 58/M Spinal stenosis L2-3,3-4,4-5 Posterior decompression and instrumented posterolateral fusion L2-3-4-5
24 68/F Spinal stenosis L3-4,4-5 Posterior decompression and instrumented posterolateral fusion L3-4-5
Table 2.
Geographic data on blood loss, operation time, changes of Hb, selected protocol
No Preop Hb Immediate Postop Hb POD1d Hb POD7d Hb POD14d Hb POD3M Hb Preop Intraop Postop Blood loss OP time
01 12.8 10.2 08.4 09.5 09.4 09.7 EPO2 CS No 0900 170
Ferr
02 12.8 11.4 11.6 10.8 11.9 12.1 No ANH No 0500 100
03 14.5 09.9 11.2 13.4 13.4 13.6 No ANH No 0470 100
04 08.6 06.7 06.6 09.6 09.6 10.1 EPO4 ANH EPO2 0800 090
Veno CS Veno
05 13.0 10.4 06.3 08.3 09.3 10.3 EPO4 No EPO2 0700 110
Veno Veno
06 13.1 09.5 08.6 08.1 08.4 10.2 EPO2 ANH No 0500 090
Ferr
07 13.9 10.4 09.7 09.0 09.0 11.2 EPO2 ANH EPO2 0900 130
Ferr CS Veno
08 12.5 10.4 10.8 10.3 10.8 11.1 EPO2 ANH No 0520 090
Ferr
09 10.8 10.3 10.6 10.2 11.1 11.0 EPO2 ANH No 0480 100
Ferr
10 12.0 09.5 07.1 06.7 07.4 09.1 EPO2 ANH EPO2 0450 090
Ferr Veno
11 12.5 12.2 12 11.9 11.9 11.3 EPO2 ANH No 0500 100
Ferr
12 11.6 08.5 07.9 08.5 10.0 11.1 EPO2 ANH EPO2 1200 130
Ferr CS Veno
13 13.8 10.2 07.2 09.8 10.1 10.8 EPO2 ANH EPO2 0640 100
Ferr Veno
14 12.7 09.8 08.5 10.2 10.1 11.5 EPO2 CS No 0700 110
Ferr
15 10.6 08.7 08.3 08.8 09.7 09.5 EPO4 ANH No 0460 100
Veno CS
16 12.3 10.5 09.1 09.8 10.2 10.5 EPO2 ANH No 0650 100
Ferr
17 12.7 09.7 07.7 08.5 09.5 10.4 No CS EPO2 0500 110
Veno
18 14.7 11.0 10.1 11.2 10.8 12.1 No ANH No 0800 090
19 12.0 09.5 06.8 08.6 08.5 09.7 EPO2 ANH EPO2 0500 100
Ferr CS Veno
20 13.7 07.9 08.2 09.5 10.1 10.5 No ANH No 0450 120
21 11.6 09.2 08.5 09.8 10.6 11.0 EPO2 ANH No 0500 100
Ferr
22 12.5 08.2 07.5 08.6 09.1 09.8 EPO2 ANH EPO2 0600 090
Ferr Veno
23 10.6 08.1 07.2 07.9 08.5 09.2 EPO2 No EPO2 0800 120
Ferr Ferr
24 11.0 09.2 08.5 09.5 10.6 12.0 EPO2 ANH No 0550 100
Ferr

Hb: Hemoglobin (g/dl); EPO2: Recombinant Erythropoietin 2000 unit; EPO4: Recombinant Erythropoietin 4000 unit; Ferr: Ferrum Pola �(Ferric hydroxide-polymaltose complex 357 mg, Folic acid 350 mcg); ANH: Acute normovolemic hemodilution; CS: Cell saver; Veno: Venoferrum � (Ferric hydroxide sucrose complex)

Table 3.
Protocol for pre and postoperation
적응증 Hb (g/dl) 치료
급성 및 만성 7~10 EPO 4000단위를 주 3회, 1일 1회, 피하로 주사
Ferrum Pola 2T 1일 1회, 매일 경구 투여 또는 Venoferrum 1 앰플을 1일 1회,
매일 생리 식염수 50 cc에 섞어서 30분 이상의 시간을 두고 천천히 정맥 주사
출혈에 의한 빈혈 5~7 EPO 8000단위를 주 3회, 1일 1회, 피하로 주사
Ferrum Pola 2T 1일 1회 또는 매일 경구 투여 Venoferrum 1 앰플을 1일 1회, 매
일 생리 식염수 50cc에 섞어서 30분 이상의 시간을 두고 천천히 정맥 주사
5 미만 EPO 12000단위를 주 3회, 1일 1회, 피하로 주사
매일 Venoferrum 1 앰플을 1일 2회, 매일 생리 식염수 50 cc에 섞어서 30분 이상
의 시간을 두고 천천히 정맥 주사
수술 전 10 이상 수술 2주 전부터 EPO 2000단위를 주 3회, 1일 1회, 피하로 주사
수술 2주 전부터 Ferrum Pola 2T 1일 1회, 매일 경구 투여
5~10 수술 2주 전부터 EPO 4000단위를 주 3회, 1일 1회, 피하로 주사
Ferrum Pola 2T 1일 1회, 매일 경구 투여 또는 Venoferrum 1 앰플을 1일 1회,
매일 생리 식염수 50 cc에 섞어서 30분 이상의 시간을 두고 천천히 정맥 주사
5 미만 수술 2주 전부터 EPO 8000단위를 매일 1일 1회, 피하로 주사
Venoferrum 1 앰플을 1일 1회, 매일 생리 식염수 50 cc에 섞어서 30분 이상의 시
간을 두고 천천히 정맥 주사
수술 후 5~7 EPO 4000단위를 주 3회, 1일 1회, 피하로 주사
Venoferrum 1 앰플을 1일 1회, 매일 생리 식염수 50 cc에 섞어서 30분 이상의 시
간을 두고 천천히 정맥 주사
8 이상 EPO나 Iron 제재는 사용하지 않아도 되며, 수술 후 출혈 경향을 세심하게 관찰한다
수술 후 출혈 시 신속히 재수술을 시행한다.
재수술 후 환자의 Hb이 저하되었을 때 위의 수술 전 절차에 따라 EPO와 Iron 제
재를 투여한다.
Table 4.
Drugs for pre and postoperation
약제 단위 및 종류 투여 방법 작용
Recombinant Human Erythropoietin 2000 unit SC 적혈구 조혈을 위한 합성 호르몬 제제로서, 만성 신부
전 환자, 미숙아, 수술 전 자가 수혈을 계획하는 환자,
만성 질환으로 인한 빈혈, 암환자의 빈혈 등의 치료에
널리 사용되어짐.
4000 unit SC 암환자의 경우 내인성 EPO의 level이 낮은 환자에게
투여할 때도 효과가 있지만, EPO levlel이 높은 환자에
게도 효과가 있음이 보고되었음.
Iron Feroba-You � PO 경구용 빈혈치료제/1정당 철분 80 mg이 함유된 고함
량 철분제
Hemocontin � PO 경구용 빈혈치료제/1정당 철분 100 mg이 함유된 고함
량 철분제
Hemo Q � PO 경구용 빈혈치료제/1 앰플당 철분 40 mg이 함유된 고
함량 철분제
Venoferrum � IV 철 결핍성 빈혈에 대해 우수한 치료 효과를 가진 빈
혈 치료제 1앰플당 철분 100 mg/ 경구용 사용이 불가
능하거나 필요 시
Aprotinin 10만 unit IV Serin protease inhibiter의 일종으로, kallikrein과 plas-
min 같은 몇 가지 serin protease의 작용을 억제시킨다.
Antifibrinolytic aminoacids 보다 출혈을 멈추는 범위가
더 넓은 것으로 보이며, 혈액이 외부 표면과 접하면서
일어나는 혈액 응고와 fibrinolysis 반응을 동시에 억제
시킴.
20만 unitIV 주의사항- 투여 전에 반드시 6개월 이내 aprotinin을
사용한 적이 있었는지 확인할 것. 8%에서 Ag/Ab reac-
tion이 보고됨.
TOOLS
Similar articles